Last reviewed · How we verify

DTPa-HBV-IPV/Hib vaccine

GlaxoSmithKline · Phase 3 active Biologic

DTPa-HBV-IPV/Hib vaccine is a Vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b in infants and children.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameDTPa-HBV-IPV/Hib vaccine
SponsorGlaxoSmithKline
Drug classVaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTPa-HBV-IPV/Hib is a hexavalent vaccine containing inactivated antigens from six pathogens. The diphtheria and tetanus components are toxoids (inactivated toxins), the acellular pertussis component contains purified bacterial antigens, hepatitis B contains recombinant surface antigen, IPV contains inactivated poliovirus strains, and Hib contains conjugated polysaccharide capsule. Together, these antigens trigger both humoral and cell-mediated immune responses to provide protection against these six infectious diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTPa-HBV-IPV/Hib vaccine

What is DTPa-HBV-IPV/Hib vaccine?

DTPa-HBV-IPV/Hib vaccine is a Vaccine drug developed by GlaxoSmithKline, indicated for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b in infants and children.

How does DTPa-HBV-IPV/Hib vaccine work?

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b.

What is DTPa-HBV-IPV/Hib vaccine used for?

DTPa-HBV-IPV/Hib vaccine is indicated for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b in infants and children.

Who makes DTPa-HBV-IPV/Hib vaccine?

DTPa-HBV-IPV/Hib vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is DTPa-HBV-IPV/Hib vaccine in?

DTPa-HBV-IPV/Hib vaccine belongs to the Vaccine class. See all Vaccine drugs at /class/vaccine.

What development phase is DTPa-HBV-IPV/Hib vaccine in?

DTPa-HBV-IPV/Hib vaccine is in Phase 3.

What are the side effects of DTPa-HBV-IPV/Hib vaccine?

Common side effects of DTPa-HBV-IPV/Hib vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability or fussiness, Drowsiness, Loss of appetite.

Related